Sale!

MAFIgH MM Test

Original price was: 1,400 د.إ.Current price is: 1,050 د.إ.

-25%

The “MAFIgH MM Test” offered at DNA Labs UAE is a specialized medical examination designed to assess specific health markers or genetic conditions. With a test cost of 1050 AED, this analysis provides valuable insights into the patient’s medical status, aiding in the diagnosis, treatment planning, or risk assessment for certain diseases. Conducted in the state-of-the-art facilities of DNA Labs UAE, the test ensures accuracy and reliability in results, leveraging advanced technology and expert analysis. Patients seeking comprehensive health evaluations can consider the MAFIgH MM Test as part of their proactive health management strategy.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

MAFIgH MM Test – Cost, Symptoms, Diagnosis

Test Name: MAFIgH MM Test

Components: Sodium Heparin Vacutainer (2ml)

Price: 1050.0 AED

Sample Condition: Bone Marrow / Peripheral blood

Report Delivery: 3-4 days

Method: FISH

Test Type: Genetics

Doctor: Oncology

Test Department:

Pre Test Information: MAF/IgH (MM) can be done with a Doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Details

MAF/IgH (MM) stands for “MAF (MafB) and IgH (Immunoglobulin Heavy Chain)” translocation in multiple myeloma (MM). Multiple myeloma is a type of cancer that affects plasma cells, which are a type of white blood cell that produces antibodies.

In some cases of multiple myeloma, there is a genetic abnormality called a translocation, where parts of two different chromosomes break off and swap places. The MAF gene, specifically the MafB protein, and the IgH gene (Immunoglobulin Heavy Chain gene) are involved in this translocation. The MafB protein is a transcription factor that regulates gene expression, while the IgH gene is responsible for the production of antibodies.

The MAF/IgH translocation in multiple myeloma results in the overexpression of MafB, which can lead to abnormal cell growth and proliferation. It also affects the regulation of the IgH gene, leading to dysregulation of antibody production.

Understanding the MAF/IgH translocation in multiple myeloma is important for diagnosis, prognosis, and treatment planning for patients with this type of cancer. It may also serve as a potential target for therapeutic interventions in the future.

Test Name MAFIgH MM Test
Components Sodium Heparin Vacutainer (2ml)
Price 1050.0 AED
Sample Condition Bone Marrow \/ Peripheral blood
Report Delivery 3-4 days
Method FISH
Test type Genetics
Doctor Oncology
Test Department:
Pre Test Information MAF/IgH (MM) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

MAF/IgH (MM) stands for “MAF (MafB) and IgH (Immunoglobulin Heavy Chain)” translocation in multiple myeloma (MM). Multiple myeloma is a type of cancer that affects plasma cells, which are a type of white blood cell that produces antibodies. In some cases of multiple myeloma, there is a genetic abnormality called a translocation, where parts of two different chromosomes break off and swap places.

The MAF gene, specifically the MafB protein, and the IgH gene (Immunoglobulin Heavy Chain gene) are involved in this translocation. The MafB protein is a transcription factor that regulates gene expression, while the IgH gene is responsible for the production of antibodies.

The MAF/IgH translocation in multiple myeloma results in the overexpression of MafB, which can lead to abnormal cell growth and proliferation. It also affects the regulation of the IgH gene, leading to dysregulation of antibody production.

Understanding the MAF/IgH translocation in multiple myeloma is important for diagnosis, prognosis, and treatment planning for patients with this type of cancer. It may also serve as a potential target for therapeutic interventions in the future.